Track hit to lead campaigns of all approved small molecules
- alpelisib (Piqray; Novartis)
- erdafitinib (Balversa; Astex -> Janssen)
- darolutamide (Nubeqa; Orion -> Bayer)
- fedratinib (Inrebic; TargeGen -> Sanofi -> Celgene)
- selinexor (Xpovio; Karyopharm Therapeutics)
- entrectinib (Rozlytrek; Roche)
- glasdegib (Daurismo; Pfizer)